The Second Pluripotency and Reprogramming Symposium
Human pluripotent stem cells possess the ability to self renew in vitro while maintaining a developmental plasticity that is similar to that exhibited by progenitor cells of the very early embryo. As a result, pluripotent stem cells may provide an inexhaustible supply of any differentiated cell type for both in vitro studies of disease and regenerative medicine.
The discovery of reprogramming methods that rely on defined transcription factors and their use in the derivation of patient-specific iPS cell lines have greatly expanded the potential utility of pluripotent cells. Patient-specific iPS cells have already enabled in vitro studies of diseases including spinal muscular atrophy, familial dysautonomia and LEOPARD syndrome. Future applications of human pluripotent stem cell lines could also include the study of common diseases that arise as the result of complex interactions between a patient’s genotype and their environment. Finally, pluripotent cells will eventually serve as a renewable source of both autologous cells and tissue for transplantation and regenerative medicine.
Our second symposium will feature world leaders who will describe their latest advances in stem cell biology and reprogramming.